• For Institutions

    • Corporate Services
    • Developers
  • Download
  • Help
  • About

    • Company Profile
    • License & Regulatory
    • Media coverage
longbridgelongbridge
longbridgelongbridge
Products
Pricing
Markets
Global Markets
Stock Screener
Information
Insights
News
Live
Academy
Affiliate Program
Promotions
PortAI
EN
English
简体中文
繁體中文
繁體中文(廣東話)Posts & comments will be shown in Cantonese
Search...
Quote ListQuote List
Overview
News
Financials
© 2025 Longbridge|Disclaimer

Event Tracking

Dec10
Mizuho Securities Analyst Reiterates Buy Rating for Nurix Therapeutics
13:38
Dec8
Stifel Nicolaus Maintains Buy Rating on Nurix Therapeutics
13:32
Nurix Therapeutics Unveils Phase 1 Trial Data of Bexobrutideg at ASH Annual Meeting
13:07
Nov7
Oppenheimer Reiterates Buy Rating on Nurix Therapeutics
19:56
Nov4
Gil Blum gives Nurix Therapeutics' bexodeg a buy rating
10:16
Oct23
Nurix Therapeutics Maintained at Hold Rating
08:47

Schedules & Filings

Schedules
Filings
Oct9
Earning Release(EST)

FY2025 Q3 Earning Release (USD) Revenue 7.894 M, Net Income -86.42 M, EPS -1.0268

Jul9
Earning Release(EST)

FY2025 Q2 Earning Release (USD) Revenue 44.06 M, Net Income -43.46 M, EPS -0.5181

Apr8
Earning Release(EST)

FY2025 Q1 Earning Release (USD) Revenue 18.45 M, Net Income -56.35 M, EPS -0.6743

View More

Stock List

Top Gainers
Top Decliners
China Concepts
Symbol
Price
%Chg
Change
PFSA
0.1412
+106.73%
+0.073
AEHL
2.113
+86.99%
+0.990
EKSO
10.055
+84.16%
+4.610
OCG
0.1347
+62.09%
+0.052
CETX
3.245
+53.79%
+1.130
BRLS
2.340
+45.34%
+0.700
FLYE
7.528
+42.45%
+2.245
ONTF
8.010
+36.69%
+2.150
ZCMD
0.6029
+33.21%
+0.150
FONR
18.770
+28.04%
+4.110
View More